These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 17616639)

  • 1. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
    Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
    Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
    Morse MA; Hobeika AC; Osada T; Serra D; Niedzwiecki D; Lyerly HK; Clay TM
    Blood; 2008 Aug; 112(3):610-8. PubMed ID: 18519811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
    Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
    Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
    Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
    J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
    Frankel AE; Surendranathan A; Black JH; White A; Ganjoo K; Cripe LD
    Cancer; 2006 May; 106(10):2158-64. PubMed ID: 16586495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IL-2 diphtheria toxin fusion protein denileukin diftitox modulates the onset of diabetes in female nonobese diabetic animals in a time-dependent manner and breaks tolerance in male nonobese diabetic animals.
    Zinser E; Rössner S; Littmann L; Pangratz N; Schuler G; Steinkasserer A
    J Immunol; 2012 Aug; 189(3):1173-81. PubMed ID: 22730534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of human regulatory T cells.
    Hobeika AC; Morse MA; Osada T; Peplinski S; Lyerly HK; Clay TM
    Methods Mol Biol; 2011; 707():219-31. PubMed ID: 21287338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
    J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
    Gritzapis AD; Voutsas IF; Baxevanis CN
    Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine combined with nonlytic interleukin 2/Fc fusion protein improves immune response to hepatitis B vaccination in a mouse skin transplantation model.
    Li Z; Zhang D; Gao J; Li WX; Zhu JY
    Transplant Proc; 2013; 45(6):2559-64. PubMed ID: 23953581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.
    Cheung LS; Fu J; Kumar P; Kumar A; Urbanowski ME; Ihms EA; Parveen S; Bullen CK; Patrick GJ; Harrison R; Murphy JR; Pardoll DM; Bishai WR
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3100-3105. PubMed ID: 30718426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
    Gupta S; Cheung L; Pokkali S; Winglee K; Guo H; Murphy JR; Bishai WR
    J Infect Dis; 2017 Jun; 215(12):1883-1887. PubMed ID: 28863467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Foss F; Demierre MF; DiVenuti G
    Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.
    Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial.
    Luke JJ; Zha Y; Matijevich K; Gajewski TF
    J Immunother Cancer; 2016; 4():35. PubMed ID: 27330808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma.
    Ansell SM; Tang H; Kurtin PJ; Koenig PA; Nowakowski GS; Nikcevich DA; Nelson GD; Yang Z; Grote DM; Ziesmer SC; Silberstein PT; Erlichman C; Witzig TE
    Leukemia; 2012 May; 26(5):1046-52. PubMed ID: 22015775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
    Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
    J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.
    Baur AS; Lutz MB; Schierer S; Beltrame L; Theiner G; Zinser E; Ostalecki C; Heidkamp G; Haendle I; Erdmann M; Wiesinger M; Leisgang W; Gross S; Pommer AJ; Kämpgen E; Dudziak D; Steinkasserer A; Cavalieri D; Schuler-Thurner B; Schuler G
    Blood; 2013 Sep; 122(13):2185-94. PubMed ID: 23958949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo.
    Jiang Q; Zhang L; Wang R; Jeffrey J; Washburn ML; Brouwer D; Barbour S; Kovalev GI; Unutmaz D; Su L
    Blood; 2008 Oct; 112(7):2858-68. PubMed ID: 18544681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.